Search results
Results from the WOW.Com Content Network
A 2005 placebo-controlled study looked at men and women aged 45 to 65 with midlife-onset major or minor depression. Participants followed a six-week DHEA treatment plan that included 90 milligrams ...
Plasma levels of DHEA in adult men are 10 to 25 nM, in premenopausal women are 5 to 30 nM, and in postmenopausal women are 2 to 20 nM. [25] Conversely, DHEA-S levels are an order of magnitude higher at 1–10 μM. [25] Levels of DHEA and DHEA-S decline to the lower nanomolar and micromolar ranges in men and women aged 60 to 80 years. [25]
In premenopausal women, 40 to 75% of circulating testosterone is derived from peripheral metabolism of DHEA-S, and in postmenopausal women, over 90% of estrogens, mainly estrone, are derived from peripheral metabolism of DHEA-S. [2] A study found that administration of exogenous DHEA-S in women who were pregnant increased circulating levels of ...
Hyperandrogenism is a medical condition characterized by high levels of androgens.It is more common in women than men. [4] Symptoms of hyperandrogenism may include acne, seborrhea, hair loss on the scalp, increased body or facial hair, and infrequent or absent menstruation.
An online survey conducted by the Cleveland Clinic of 1,174 men 18 years or older, found that 72% of men would rather do household tasks, such as cleaning the bathroom or mowing the lawn, than see ...
Now, new research finds that women who use hormone therapy after age 65 are usually fine to do just that — but the dose and timing of the treatment matter. The study, which was published in ...
Prasterone, also known as dehydroepiandrosterone (DHEA) and sold under the brand name Intrarosa among others, is a medication as well as over-the-counter dietary supplement which is used to correct DHEA deficiency due to adrenal insufficiency or old age, as a component of menopausal hormone therapy, to treat painful sexual intercourse due to vaginal atrophy, and to prepare the cervix for ...
The study, which involved 106 peri- and postmenopausal women and was presented at the Endocrine Society’s annual meeting in May, indicates women should self-monitor their vasomotor symptoms and ...